{
    "doi": "https://doi.org/10.1182/blood.V130.Suppl_1.4151.4151",
    "article_title": "Validation of the NCCN-IPI and the Geltamo-IPI in a Large Cohort of Patients Diagnosed of Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP/R-CHOP-like in a Single Institution ",
    "article_date": "December 7, 2017",
    "session_type": "627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)\u2014Results from Retrospective/Observational Studies: Poster III",
    "abstract_text": "Introduction: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease and the identification of risk groups is important to plan different therapeutic strategies. The International Prognostic Index (IPI) has been an easy and universal prognostic index during the past 20 years. New prognostic indexes are needed to improve the identification of higher risk groups. The objective of this study is to validate and compare the National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) and the Grupo Espa\u00f1ol de Linfomas/Trasplante de M\u00e9dula \u00f3sea (GELTAMO-IPI) in a large cohort of DLBCL patients treated homogeneously with immunochemotherapy in a single institution. Methods: 371 adults with de novo DLBCL consecutive diagnosed from 2004 to 2016 at Insitut Catal\u00e0 d'Oncologia in Barcelona and treated with curative intention based on immunochemotherapy [310(81%) R-CHOP, 61 (19%) R-CHOP-like] were included in the analyses. Prognostic indexes were compared in patients with complete data: NCCN-IPI vs. IPI (371 patients) and GELTAMO IPI vs. IPI (268 patients). All survival curves were obtained by the Kaplan-Meier method, and compared using the log-rank test. Results: The number of patients in the low risk (LR), low-intermediate risk (LIR), High-intermediate risk (HIR) and high risk (HR) groups are shown in table 1. OS curves for each prognostic index are shown in Figure 1. In all the risk indexes, the four risk groups had 5-yearOS and PFS rates with significant differences in the global comparisons. The NCCN-IPI discriminated better low-risk subgroups than IPI (5-year OS: 90.6% vs 75.5%, respectively). The GELTAMO-IPI compared to IPI improved the discrimination of the LR group (5-year OS: 81.8% vs 75.5%, respectively) and the HR group (5-year OS: 26.4% vs 39.4%, respectively). Conclusion: GELTAMO-IPI has been validated in an independent cohort of patients equally treated in a single centre. GELTAMO-IPI is a good prognosis index capable of differentiating a high-risk group with a 5-year OS of 26% unlike NCCN-IPI and IPI. View large Download slide View large Download slide Close modal Disclosures No relevant conflicts of interest to declare.",
    "topics": [
        "cyclophosphamide, doxorubicin, prednisone, and vincristine",
        "diffuse large b-cell lymphoma",
        "national comprehensive cancer network",
        "r-chop",
        "kaplan-meier survival curve",
        "log rank test",
        "risk identification",
        "survival curve",
        "heterogeneity"
    ],
    "author_names": [
        "Maria Queralt Salas Gay, MD",
        "Santiago Mercadal, MD",
        "Eva Domingo Domenech, MD",
        "Ana C Oliveira, MD PhD",
        "Maite Encuentra",
        "Fina Climent, MD PhD",
        "Cristina Baca Cano, MD",
        "Marcio Andrade-Campos, MD PhD",
        "Esmeralda De la Banda, MD",
        "Carmen Aguilera",
        "Alberto Fernandez de Sevilla, MD PhD",
        "Anna Sureda",
        "Eva Gonz\u00e1lez-Barca, MD PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Maria Queralt Salas Gay, MD",
            "author_affiliations": [
                "Hospital Duran i Reynals, Hospital Duran i Reynals, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Santiago Mercadal, MD",
            "author_affiliations": [
                "Hospital Duran i Reynals, Hospital, L'Hospitalet De Llobregat, ESP ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eva Domingo Domenech, MD",
            "author_affiliations": [
                "Hospital Duran i Reynals, Hospital, Barcelona, Spain ",
                "Department of Clinical Hematology, Institut Catal\u00e0 d'Oncologia - Hospital Duran I Reynals, IDIBELL, Barcelona, Spain ",
                "Hospital Duran i Reynals, Institut Catal\u00e0 d'Oncologia, IDIBELL, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ana C Oliveira, MD PhD",
            "author_affiliations": [
                "Department of Clinical Hematology, Institut Catal\u00e0 d'Oncologia - Hospital Duran I Reynals, IDIBELL, Barcelona, Spain ",
                "Hospital Duran i Reynals, Institut Catal\u00e0 d'Oncologia, IDIBELL, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Maite Encuentra",
            "author_affiliations": [
                "Clinical Investigation Unit, Institut Catal\u00e0 d'Oncologia - Hospital Duran I Reynals, IDIBELL, Barcelona, Spain ",
                "Unidad de Ensayos Cl\u00ednicos, Institut Catal\u00e0 d'Oncologia, IDIBELL, BARCELONA, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Fina Climent, MD PhD",
            "author_affiliations": [
                "Hospital Universitario de Bellvitge, Hospital, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Cristina Baca Cano, MD",
            "author_affiliations": [
                "Hospital Duran i Reynals, Hospital, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marcio Andrade-Campos, MD PhD",
            "author_affiliations": [
                "Hospital Duran i Reynals, Hospital, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Esmeralda De la Banda, MD",
            "author_affiliations": [
                "Laboratory of Hematology, Hospital Universitari Bellvitge, IDIBELL, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carmen Aguilera",
            "author_affiliations": [
                "Department of Clinical Hematology, Institut Catal\u00e0 d'Oncologia - Hospital Duran I Reynals, IDIBELL, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alberto Fernandez de Sevilla, MD PhD",
            "author_affiliations": [
                "Department of Clinical Hematology, Institut Catal\u00e0 d'Oncologia - Hospital Duran I Reynals, IDIBELL, Barcelona, Spain ",
                "Hospital Duran i Reynals, Institut Catal\u00e0 d'Oncologia, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Anna Sureda",
            "author_affiliations": [
                "Department of Clinical Hematology, Institut Catal\u00e0 d'Oncologia - Hospital Duran I Reynals, IDIBELL, Barcelona, Spain ",
                "Hospital Duran i Reynals. Institut Catal\u00e0 d'Oncologia., Hematology Department, Hospital Duran i Reynals. Institut Catal\u00e0 d'Oncologia., Spain, Barcelona, Spain ",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Eva Gonz\u00e1lez-Barca, MD PhD",
            "author_affiliations": [
                "Department of Clinical Hematology, Institut Catal\u00e0 d'Oncologia - Hospital Duran I Reynals, IDIBELL, Barcelona, Spain ",
                "Hospital Duran i Reynals, Institut Catal\u00e0 d'Oncologia, IDIBELL, Barcelona, Spain ",
                "Hospital Duran i Reynals, INSTITUT CATALA D'ONCOLOGIA, BARCELONA, ESP",
                "Department of Hematology, Institut Catal\u00e0 d'Oncologia, L'Hospitalet de LLobregat, Hospitalet, Spain "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-09T09:35:31",
    "is_scraped": "1"
}